Your browser doesn't support javascript.
loading
Golimumab Therapy in Ulcerative Colitis / 대한소화기학회지
The Korean Journal of Gastroenterology ; : 64-73, 2016.
Article in Korean | WPRIM | ID: wpr-204982
ABSTRACT
Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-alpha) antibodies including infliximab, adalimumab, and golimumab. Golimumab, a new anti-TNF-alpha agent has been recently approved for patients with moderate to severe ulcerative colitis. Its efficacy and safety has been demonstrated in line with infliximab and adalimumab in preclinical and clinical studies. This review will focus on golimumab therapy in ulcerative colitis.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Drug Administration Schedule / Colitis, Ulcerative / Clinical Trials as Topic / Tumor Necrosis Factor-alpha / Treatment Outcome / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal Limits: Humans Language: Korean Journal: The Korean Journal of Gastroenterology Year: 2016 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Drug Administration Schedule / Colitis, Ulcerative / Clinical Trials as Topic / Tumor Necrosis Factor-alpha / Treatment Outcome / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal Limits: Humans Language: Korean Journal: The Korean Journal of Gastroenterology Year: 2016 Type: Article